BioNTech said on Monday it plans to set up a regional headquarters and build a new manufacturing site for its vaccines based on messenger RNA technology (mRNA) in Singapore, in the latest move to expand its production network.

The biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-based vaccines depending on the specific type, once it is operational in 2023...